research library

• Safety and side effects of cannabidiol

• CBD: From an inactive cannabinoid to a drug with wide spectrum of action

• CBD as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress

• CBD: An overview of some pharmacological aspects

• CBD: An overview of some chemical and pharmacological aspects

• The endocannabinoid system as an emerging target of pharmacotherapy

• Therapeutic potential of cannabinoid-based drugs

• Targeting the endocannabinoid system with cannabinoid receptor agonists

• Cannabis-based medicines–GW pharmaceuticals

• The therapeutic potential of cannabis and cannabinoids

• Emerging strategies for exploiting cannabinoid receptor agonists as medicines

• Therapeutic potential of cannabinoid-based drugs

• Cannabinoids in clinical practice

• Cannabinoids

• Pharmacology of cannabinoids

• Combined cannabinoid therapy via an oromucosal spray

• Non-psychotropic plant cannabinoids

• Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

• Care and feeding of the endocannabinoid system

• Understanding the molecular aspects of THC and CBD as antioxidants

• A tale of two cannabinoids

• Clinical Studies With Cannabis and Cannabinoids

• Gut feelings about the endocannabinoid system

• Letters to Nature: Leptin-regulated endocannabinoids are involved in maintaining food intake

• The endocannabinoid system in targeting inflammatory neurodegenerative diseases

• That which we call Indica, by any other name would smell as sweet

• An Overview of the Endogenous Cannabinoid System: Components and Possible Roles of this Recently Discovered Regulatory System

• Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

• Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

• Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases

• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

• Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa

• Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

• Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

• The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content

• CBD as a Treatment for Acne?

• CBD exerts sebostatic and antiinflammatory effects on human sebocytes

• The endocannabinoid system of the skin in health and disease

• Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling

• Endocannabinoid signaling and epidermal differentiation

• Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease

• The therapeutic potential of the endocannabinoid system for Alzheimer’s disease

• Endocannabinoid signalling in Alzheimer’s disease

• A molecular link between the active component of marijuana and Alzheimer’s disease pathology

• Neuroprotective effect of CBD... on beta-amyloid-induced toxicity in PC12 cells

• The Potential Therapeutic Effects of THC on Alzheimer’s Disease

• The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease

• Cannabinoids for the treatment of dementia

• CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression

• CBD: A promising drug for neurodegenerative disorders?

• Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition

• The role of the endocannabinoid system in Alzheimer’s disease

• The role of phytochemicals in the treatment and prevention of dementia

• Cannabinoids for the treatment of dementia  

• Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement

• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic   

• Antibacterial cannabinoids from Cannabis sativa: A structure-activity study (PubMed)

• Antibacterial activity of delta9-THC and CBD

• CBD as an anxiolytic drug

• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa

• CBD reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients

• Neural basis of anxiolytic effects of CBD in generalized social anxiety disorder

• Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation

• Effects of CBD on regional cerebral blood flow

• The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors

• The anxiolytic effect of CBD on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system

• Plant-based medicines for anxiety disorders, part 2

• Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis

• The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

• Involvement of the endocannabinoid system in osteoarthritis pain

• The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55  

• Endocannabinoid Signaling in Autism

• Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain

• Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders

• A novel approach to the symptomatic treatment of autism

• Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders

• Targeting the endocannabinoid system in the treatment of fragile X syndrome

• Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  

• Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial

• Inhibition of tumor angiogenesis by cannabinoids

• Cannabinoids as therapeutic agents in cancer: current status and future implications

• Cannabidiol as potential anticancer drug

• Cannabinoids for Cancer Treatment: Progress and Promise

Biliary Tract Cancer

• The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration

Blood Cancer

• Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation

• Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria

• Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease

Brain Cancer

• Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas

• Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines

• A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

• Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells

• Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor

• The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model

• Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor‐independent mechanism

• Cannabinoids and gliomas

Breast Cancer

• Cannabinoids: a new hope for breast cancer therapy?

• Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

• Δ9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation

• Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma

• Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells

• Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

• Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation 1

• Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancergrowth and invasion

• Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration

Colorectal Cancer

• Cannabinoids in intestinal inflammation and cancer

• The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2

Liver Cancer

• Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy

Lung Cancer

• Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis

• Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1

• Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo

Mouth & Throat Cancer

• Cannabinoids inhibit cellular respiration of human oral cancer cells

Ovarian Cancer

• Cannabinoid receptors as a target for therapy of ovarian cancer

Prostate Cancer

• Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production

• The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications

• Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16INK4a/pRB pathway

Skin Cancer

• Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors

Uterine, Testicular, & Pancreatic Cancer

• Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes

• Cannabis and cannabinoids

• CBD in inflammatory bowel diseases: a brief overview  

• Cannabis finds its way into treatment of Crohn’s disease

• CBD reduces intestinal inflammation through the control of neuroimmune axis

• Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis  

• The effects of Delta-tetrahydrocannabinol and CBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis  

• Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice  

• Cannabinoids and the gut: New developments and emerging concepts

• Endocannabinoids and the gastrointestinal tract  

• Cannabinoids and gastrointestinal motility: Animal and human studies  

• Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis

• Endocannabinoid system dysfunction in mood and related disorders  

• Antidepressant-Like and Anxiolytic-Like Effects of CBD

• The endocannabinoid system and the treatment of mood and anxiety disorders  

• Endocannabinoid signaling in the etiology and treatment of major depressive illness  

• Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors  

• Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants  

• Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa  

• Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress

• Serum contents of endocannabinoids are correlated with blood pressure in depressed women  

• The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants  

• Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures  

• Report of a parent survey of CBD-enriched cannabis use in pediatric treatment-resistant epilepsy

• Medicinal marijuana stops seizures, brings hope to a little girl  

• Cannabinoids for epilepsy  

• Cannabis, CBD, and epilepsy – From receptors to clinical response

• The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability

• Chronic administration of CBD to healthy volunteers and epileptic patients  

• Endocannabinoid system protects against cryptogenic seizures

• Seizing an opportunity for the endocannabinoid system

• Cannabidiol: promise and pitfalls  

• Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and otherneuropsychiatricdisorders

• Report of a parent survey of cannabidiol-enriched cannabis use in pediatrictreatment-resistant epilepsy  

• From the Editors: Cannabidiol and medical marijuana for the treatment of epilepsy

• Cannabidivarin (CBDV) suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression  

• CBD exerts anti-convulsant effects in animal models of temporal lobe and partial seizures  

• Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo  

• Hypnotic and antiepileptic effects of CBD

• The cannabinoids as potential antiepileptics

• Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats  

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?  

• Cannabis use in patients with fibromyalgia

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress  

• The endocannabinoid system: an emerging key player in inflammation

• Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice  

• Cannabinoids, endocannabinoids, and related analogs in inflammation  

• Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor

• Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors  

• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis  

• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation  

• Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement

• Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption  

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation  

• Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death

• Cannabinoids in clinical practice  

• Cannabidiol in inflammatory bowel diseases: A brief overview  

• CBD reduces intestinal inflammation through the control of neuroimmune axis  

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?  

• Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation  

• Therapeutic potential of cannabinoid-based drugs  

• Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)

• CBD and the gut: New developments and emerging concepts

• Endocannabinoids and the gastrointestinal tract  

• CBD and gastrointestinal motility

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

• Effects of anandamide in migraine: data from an animal model

• Cannabinoids and hallucinogens for headache

• The endocannabinoid system and migraine

• Variations in the cannabinoid receptor 1 gene predispose to migraine

• Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders  

• The endocannabinoid system & the treatment of mood and anxiety disorders

• The endocannabinoid system & psychiatric disorders  

• The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives  

• Endocannabinoid system dysfunction in mood and related disorders  

• Effects of CBD on regional cerebral blood flow  

• Sativex for the management of multiple sclerosis symptoms  

• THC & CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis  

• Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity  

• CBD provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors  

• Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis

• Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis  

• Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis  

• A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis  

• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain  

• Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain  

• Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system  

• CBD, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus

• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain  

• Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain

• Cannabis, pain, and sleep: Sativex Clinical Trials

• Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial

• Cannabinoids for neuropathic pain

• Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue

• Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis

• The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

• Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy  

• Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain

• Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action

• Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors  

• Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes  

• Cannabinoids in the management of difficult to treat pain  

• Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  

• Marijuana extract helps prevent chemo pain

• CBD Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts

• Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies  

• Cannabinoids and bone: Friend or foe?  

• Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells  

• Cannabinoids and the skeleton: From marijuana to reversal of bone loss  

• The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy

• The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption  

• Endocannabinoids and the regulation of bone metabolism  

• Cannabinoid receptors and the regulation of bone mass

• Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health  

• Peripheral cannabinoid receptor, CB2, regulates bone mass  

• Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors

• Long-chain polyunsaturated fatty acids may mutually benefit both obesity and osteoporosis  

• Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family  

• The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD

• Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks  

• Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear  

• Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors  

• CBD blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors  

• Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis

• Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence  

• Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment  

• The endocannabinoid system and extinction learning  

• A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers

• Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit  

• Non-antidepressant long-term treatment in post-traumatic stress disorder  

• The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress

• Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis  

• CBD exerts sebostatic and antiinflammatory effects on human sebocytes

• The endocannabinoid system of the skin in health and disease

• Epigenetic control of skin differentiation genes by phytocannabinoids  

• A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ  

• Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1  

• Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation  

• Attenuation of allergic contact dermatitis through the endocannabinoid system  

• Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus

• The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent  

• Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex   

• Effects of acute systemic administration of CBD on sleep-wake cycle in rats  

• Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults  

• CBD modulates sleep in rats

• Endocannabinoid modulation of cortical up-states and NREM sleep  

• Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat

• CBD-treated rats exhibited higher motor score after cryogenic spinal cord injury

• Endogenous cannabinoid signaling is essential for stress adaptation

• Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders

• Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output

• Neuromodulators, stress and plasticity: a role for endocannabinoid signalling

• Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress

• Endocannabinoids and stress

• Stress regulates endocannabinoid-CB1 receptor signaling

• Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus

• Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance  

• Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression

• Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory  

• The anxiolytic effect of CBD on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system

• Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid